<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640848</url>
  </required_header>
  <id_info>
    <org_study_id>AC-057-103</org_study_id>
    <nct_id>NCT00640848</nct_id>
  </id_info>
  <brief_title>Almorexant in Primary Insomnia</brief_title>
  <acronym>Insomnia</acronym>
  <official_title>Multi-center, Multiple-stage, Double-blind, Randomized, Placebo-controlled, Two-way Crossover, Single-dose Study to Investigate the Effects of ACT-078573 on Sleep Measured by Polysomnography in Patients With Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midnight Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Midnight Pharma, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep
      efficiency and to assess the effects of different doses of ACT-078573 on other PSG
      parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep efficiency (%) assessed by PSG (polysomnography)</measure>
    <time_frame>Between 10pm-12am (=lights out) until 480 minutes thereafter (=lights on)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LPS (Latency to Persistent Sleep) [min] assessed by PSG (polysomnography)</measure>
    <time_frame>Time from start of recording to the beginning of the first continuous 20 epochs of non-wake</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Insomnia</condition>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>almorexant</intervention_name>
    <description>1 dose of 400 mg in two treatment sequences</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ACT-078573</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>almorexant</intervention_name>
    <description>1 dose of 200 mg in two treatment sequences</description>
    <arm_group_label>2</arm_group_label>
    <other_name>ACT-078573</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>almorexant</intervention_name>
    <description>1 dose of 100 mg in two treatment sequences</description>
    <arm_group_label>3</arm_group_label>
    <other_name>ACT-078573</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>almorexant</intervention_name>
    <description>1 dose of 50 mg mg in two treatment sequences</description>
    <arm_group_label>4</arm_group_label>
    <other_name>ACT-078573</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>almorexant</intervention_name>
    <description>1 dose of 1000 mg in two treatment sequences</description>
    <arm_group_label>5</arm_group_label>
    <other_name>ACT-078573</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women 18 - 65 years of age (inclusive).

          -  Women of childbearing potential must have a negative urine pregnancy test at the
             screening visit, the screening adaptation night, and pre-treatment and use a reliable
             method of contraception during the entire study duration and for at least 3 months
             after study drug intake.

        Reliable methods of contraception are:

          -  Barrier type devices (e.g., female condom, diaphragm, contraceptive sponge) only in
             combination with a spermicide.

          -  Intra-uterine devices.

          -  Oral, injectable, implantable or transdermal contraceptives only in combination with a
             barrier method.

               -  Abstention, rhythm method, and contraception by the partner alone are not
                  acceptable methods of contraception.

        Women not of childbearing potential are defined as prepubescent, postmenopausal (i.e.,
        amenorrhea for at least 1 year), or surgically or naturally sterile.

          -  Body mass index (BMI) between 18 and 30 kg/m2 (limits included) at screening visit.

          -  12-lead ECG without clinically relevant abnormalities at screening visit.

          -  Hematology and biochemistry test results not deviating from the normal range to a
             clinically relevant extent at screening visit and following the screening/adaptation
             night.

          -  Primary insomnia by DSM-IV-TR criteria based on medical history and the assessments
             performed at screening visit.

          -  History of the following for at least 3 months prior to the screening visit:

               -  Usual reported subjective total sleep time (TST) 3 - 6 hours.

               -  Usual sleep disturbance with a subjective sleep onset latency of &gt; 30 min.

               -  Daytime complaints associated with poor sleep (e.g., fatigue, irritability,
                  difficulty concentrating).

          -  Polysomnography (PSG) at screening/adaptation night confirming TST &lt; 6 h and LPS ≥ 20
             min.

          -  Willingness to refrain from CNS-active drugs for 5 half-lives of the respective drug
             (but at least 1 week) prior to the screening/adaptation night and up to the end of
             treatment period 2. The usage of short-acting hypnotics (defined as hypnotics with a
             half-life of up to and including 10 hours) is allowed up to 48 hours prior to each PSG
             night, i.e., prior to the screening/adaptation night and prior to the treatment PSG
             nights.

          -  Urine drug test negative for barbiturates, cannabinoids, amphetamines, and cocaine at
             screening visit 1, screening/adaptation PSG night and pre-treatment. Urine drug test
             negative for benzodiazepines and opiates at screening/adaptation PSG night and
             pre-treatment.

          -  Signed informed consent prior to any study-mandated procedure.

        Exclusion Criteria:

          -  Symptom assessment questionnaire (SBB) for diagnosis of apnea resulting in a score &gt; 2
             at screening visit.

          -  Zung self-rating depression scale (SDS) and/or Zung self-rating anxiety scale (SAS)
             resulting in a raw score ≥ 50 at screening visit.

          -  Restless legs syndrome and/or meeting all four essential diagnostic criteria for RLS
             (see Appendix 10).

          -  Insomnia due to sleep apnea or periodic limb movement disorder as assessed by PSG at
             screening/adaptation night:

               -  apnea/hypopnea index (AHI) &gt; 10/h

               -  periodic limb movement arousal index &gt; 10/h

          -  Major depressive disorder, severe psychosis, or significant anxiety disorder.

          -  Pregnancy or breast-feeding.

          -  Systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg at
             screening visit.

          -  Within the 2-month period prior to the screening visit, clinical evidence of
             alcoholism or drug abuse.

          -  Any known factor or disease that might interfere with treatment compliance, study
             conduct or interpretation of the results such as psychiatric disease or a disease
             which may affect the pharmacokinetics of the study drug.

          -  Treatment with strong inhibitors of CYP3A4 (e.g., azole derivatives, ritonavir,
             clarithromycin) within 1 week prior to the screening/adaptation PSG night and up to
             the end of treatment period 2.

          -  Excessive caffeine consumption (regular caffeine consumption of &gt; 7 units per day).

          -  Night shift workers.

          -  Known hypersensitivity to any excipients of the drug formulation.

          -  Planned treatment or treatment with another investigational drug within 1 month prior
             to randomization and up to the end of treatment period 2.

          -  Known concomitant life-threatening disease with a life expectancy &lt; 24 months.

          -  Unstable medical abnormality, significant medical disorder or acute illness.

          -  Recruitment of the same patient twice to the same dose level. Patients may be
             recruited to a lower dose level, provided that there are at least 28 days between last
             study drug administration and screening/adaptation PSG night.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jasper Dingemanse, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eleornora Chiossi, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petra Hoever, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrice Kramer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georg Dorffner, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Siesta Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Innsbruck, Dept. of Neurology Sleep Disorder Unit</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Clinic of Neurology</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, University Clinic of Psychiatrie</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Siesta Group</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scan Sleep</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glostrup University Hospital Department of Sleep Medicine</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skogby Sleep Clinic</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Research Unit, Dentalia, University of Turku</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Benjamin Franklin, Klinik und Hochschulambulanz fur Psychiatrie and Psychotherapie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Center for Sleep Medicine</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Hedwig-Krankenhaus, Akademisches Lehrkrankenhaus der Charite</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy of the University Hospital of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Valentinushaus Klinik fur Psychiatrie und Psychotherapie</name>
      <address>
        <city>Kiedrich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Giessen und Marburg, Standort Marburg, Nervenklinik</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fur Psychiatrie, Psychosomatik und Psychotherapie der Universitat am Bezirsklinikum</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOMNIBENE Institut fur Medzinische Forschung und Schlafmedizin</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technion Sleep Medicine Center, Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assuta Medical Centers</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden-Westeinde Ziekenhuis, Slaapcentrum (Holland Sleep Research)</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Ribera</name>
      <address>
        <city>Alzira</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Crue/Sant Pau, Institut de Recerca</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skaraborg Hospital, Sleep Medicine Unit, Department of Neurorehabilitation</name>
      <address>
        <city>Skoevde</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala Akademiska Hospital, Sleep Disorder Unit</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric University Clinics (UPK) Basel, Dept. for Depression Research, Sleep Medicine and Neurophysiology</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich (USZ), Neurology Polyclinic, Center for Sleep Medicine</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Edinburgh Sleep Centre</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Director, The London Sleep Centre</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <name_title>Jasper Dingemanse</name_title>
    <organization>Actelion</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

